AR062680A1 - Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas - Google Patents
Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onasInfo
- Publication number
- AR062680A1 AR062680A1 ARP070103937A ARP070103937A AR062680A1 AR 062680 A1 AR062680 A1 AR 062680A1 AR P070103937 A ARP070103937 A AR P070103937A AR P070103937 A ARP070103937 A AR P070103937A AR 062680 A1 AR062680 A1 AR 062680A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- cr7r8
- alkyl
- formula
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
Utiles en tratamiento de trastornos proliferativos celulares o una sal farmacéuticamente aceptables de las mismas. Reivindicacion 1: Un procedimiento para preparar un compuesto de formula (1) que comprende las etapas de (a) hacer resccionar un compuesto de formula (2) con un compuesto de formula (3) en la que R1 es hidrogeno, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6 o cicloalquilo C3-7; R2 es Br o I; R3 es hidrogeno, OH, -NH2, arilo, alquilo C1-8, cicloalquilo C3-7 o heterociclilo C3-7; R4 es -R5-PG seleccionado del grupo constituido por -(CR7R8)m-N(PG)R7 y -(CR7R8)m-(heterociclo de 3 a 10 miembros que comprende un átomo de anillo de N protegido con PG), y PG es un grupo protector de amino lábil a los ácidos; R5, que es R4 sin PG, es -(CR7R8)mNR7- o -(CR7R8)m-(heterociclo de 3 a 10 miembros que comprende un átomo de anillo de N), en el que m es 0, 1, 2 o 3; R6 es alquilo C1-6; y cada R7 y R8 es independientemente H o alquilo C1-6; en presencia de un catalizador de metal de transicion, una base y opcionalmente un agente de fosfina, y en un disolvente adecuado para formar un compuesto de formulas (4) o (5); y (b) haciendo reaccionar posteriormente el compuesto de formulas 4 o 5 o la mezcla de los mismos, con ácido isetionico en un disolvente adecuado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84305106P | 2006-09-08 | 2006-09-08 | |
US94210407P | 2007-06-05 | 2007-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062680A1 true AR062680A1 (es) | 2008-11-26 |
Family
ID=38988315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103937A AR062680A1 (es) | 2006-09-08 | 2007-09-06 | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas |
Country Status (15)
Country | Link |
---|---|
US (1) | US7781583B2 (es) |
EP (1) | EP2069344A2 (es) |
JP (1) | JP2008094834A (es) |
KR (1) | KR20090052385A (es) |
CN (1) | CN101511829A (es) |
AR (1) | AR062680A1 (es) |
AU (1) | AU2007297286A1 (es) |
BR (1) | BRPI0716880A2 (es) |
CA (1) | CA2662768A1 (es) |
IL (1) | IL197242A0 (es) |
MX (1) | MX2009002069A (es) |
RU (1) | RU2009108006A (es) |
TW (1) | TW200821309A (es) |
WO (1) | WO2008032157A2 (es) |
ZA (1) | ZA200901270B (es) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
MX2010006457A (es) * | 2007-12-19 | 2010-07-05 | Amgen Inc | Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular. |
ATE531372T1 (de) * | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
US8639762B2 (en) * | 2009-03-23 | 2014-01-28 | Google Inc. | Providing access to a conversation in a hosted conversation system |
EP2519526B1 (en) | 2009-12-31 | 2014-03-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Tricyclic compounds for use as kinase inhibitors |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
EP2688887B1 (en) | 2011-03-23 | 2015-05-13 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
TWI663165B (zh) | 2012-09-28 | 2019-06-21 | 美商伊格尼塔公司 | 非典型蛋白質激酶c之氮雜喹唑啉抑制劑 |
CN105008357A (zh) | 2013-02-21 | 2015-10-28 | 辉瑞大药厂 | 选择性cdk4/6抑制剂的固态形式 |
EA201892726A1 (ru) * | 2013-03-15 | 2019-04-30 | Консерт Фармасьютикалс, Инк. | Дейтерированный палбоциклиб |
CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
EP3174878A4 (en) * | 2014-07-31 | 2017-12-27 | Sun Pharmaceutical Industries Limited | A process for the preparation of palbociclib |
WO2016024249A1 (en) * | 2014-08-14 | 2016-02-18 | Sun Pharmaceutical Industries Limited | Crystalline forms of palbociclib |
WO2016030439A1 (en) * | 2014-08-28 | 2016-03-03 | Ratiopharm Gmbh | Method of producing palbociclib and pharmaceutical compositions comprising the same |
CN105111201B (zh) * | 2014-10-16 | 2017-01-11 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
CN104447739B (zh) * | 2014-11-07 | 2016-02-17 | 郑州泰基鸿诺药物科技有限公司 | 一种氘代Palbociclib衍生物、制备方法及应用 |
CN104496983B (zh) | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
CN104447743B (zh) | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
WO2016090257A1 (en) * | 2014-12-05 | 2016-06-09 | Crystal Pharmatech Inc. | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) |
CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
MX2017009270A (es) | 2015-02-03 | 2017-10-11 | Jiangsu Hengrui Medicine Co | Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion. |
CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
BR112017019286B1 (pt) | 2015-03-11 | 2023-02-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Derivados de 2h-pirazol substituídos ou um sal farmacêuticamente aceitável dos mesmos |
EP3078663A1 (en) | 2015-04-09 | 2016-10-12 | Sandoz Ag | Modified particles of palbociclib |
WO2016156070A1 (en) | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
CN104887641B (zh) * | 2015-04-08 | 2017-12-01 | 上海鲁源医药科技有限公司 | 帕布昔利布胃漂浮片及其制备方法 |
CN104910149A (zh) * | 2015-04-28 | 2015-09-16 | 上海百奇医药科技有限公司 | 一种Palbociclib制备方法 |
CN106117199A (zh) * | 2015-05-04 | 2016-11-16 | 江苏恒瑞医药股份有限公司 | 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法 |
SI3302565T1 (sl) | 2015-06-04 | 2020-02-28 | Pfizer Inc. | Trdne farmacevtske oblike palbocikliba |
CN106317053A (zh) * | 2015-06-29 | 2017-01-11 | 北大方正集团有限公司 | 一种帕博昔布晶型a的制备方法 |
ES2741958T3 (es) | 2015-08-05 | 2020-02-12 | Ratiopharm Gmbh | Nueva forma cristalina y aductos de ácido acético de palbociclib |
CN106474129A (zh) * | 2015-09-01 | 2017-03-08 | 上海方楠生物科技有限公司 | 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
WO2017036390A1 (zh) * | 2015-09-01 | 2017-03-09 | 上海方楠生物科技有限公司 | 帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
CN106632311B (zh) | 2015-11-02 | 2021-05-18 | 上海科胜药物研发有限公司 | 一种帕博西尼晶型a和晶型b的制备方法 |
CN105418603A (zh) * | 2015-11-17 | 2016-03-23 | 重庆莱美药业股份有限公司 | 一种高纯度帕布昔利布及其反应中间体的制备方法 |
CN106749259B (zh) * | 2015-11-19 | 2019-02-01 | 华东师范大学 | 一种环戊基嘧啶并吡咯类化合物的合成方法 |
CN106831759A (zh) * | 2015-12-03 | 2017-06-13 | 上海星泰医药科技有限公司 | 帕布昔利布及其中间体的制备方法 |
CN105541832A (zh) * | 2015-12-15 | 2016-05-04 | 南京艾德凯腾生物医药有限责任公司 | 一种羟乙基磺酸盐帕布昔利布的制备方法 |
CN106967061A (zh) * | 2016-01-13 | 2017-07-21 | 常州方楠医药技术有限公司 | 帕博西林的盐、晶型及其制备方法 |
CN105949189B (zh) * | 2016-06-05 | 2017-09-22 | 童明琼 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
CN106083844B (zh) * | 2016-06-05 | 2017-11-10 | 陈志明 | 一种制备抗乳腺癌药物帕博西尼中间体的方法 |
CN105924439B (zh) * | 2016-06-24 | 2017-11-24 | 石家庄海瑞药物科技有限公司 | 一种帕布昔利布的制备方法 |
US10807978B2 (en) | 2016-07-04 | 2020-10-20 | Dr. Reddy's Laboratories Limited | Process for preparation of palbociclib |
JP6870082B2 (ja) | 2016-07-07 | 2021-05-12 | プランテックス・リミテッド | 二メシル酸パルボシクリブの固体形態 |
CN106220627A (zh) * | 2016-07-31 | 2016-12-14 | 合肥远志医药科技开发有限公司 | 一种高纯度帕布昔利布的工业化制备方法 |
MD3497103T2 (ro) | 2016-08-15 | 2021-08-31 | Pfizer | Inhibitori de piridopirimidinonă CDK2/4/6 |
EP3528812B1 (en) | 2016-10-20 | 2020-12-30 | Pfizer Inc | Palbociclib for treating pah |
WO2018073574A1 (en) | 2016-10-20 | 2018-04-26 | Cipla Limited | Polymorphic forms of palbociclib |
CN106565707B (zh) * | 2016-11-03 | 2019-01-04 | 杭州科巢生物科技有限公司 | 帕博西尼新合成方法 |
WO2018091999A1 (en) | 2016-11-16 | 2018-05-24 | Pfizer Inc. | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
CN108117550B (zh) * | 2016-11-29 | 2020-08-14 | 上海医药工业研究院 | 吡啶并[2,3-d]嘧啶类化合物的制备方法 |
KR102513448B1 (ko) | 2016-12-16 | 2023-03-23 | 씨스톤 파마슈티컬즈 | Cdk4/6 억제제 |
CN108794452B (zh) | 2017-05-05 | 2021-05-28 | 上海时莱生物技术有限公司 | 具有激酶抑制活性的化合物、其制备方法和用途 |
CN109384767B (zh) * | 2017-08-08 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
JP7100125B2 (ja) | 2017-10-27 | 2022-07-12 | フレゼニウス・カビ・オンコロジー・リミテッド | リボシクリブおよびその塩の改善された調製のためのプロセス |
CN107759596A (zh) * | 2017-12-05 | 2018-03-06 | 安庆奇创药业有限公司 | 一种合成帕博西尼的方法 |
CN108586452A (zh) * | 2018-01-12 | 2018-09-28 | 重庆市碚圣医药科技股份有限公司 | 一种帕博西尼中间体的合成方法 |
CN108283940B (zh) * | 2018-01-22 | 2021-01-29 | 重庆华邦制药有限公司 | 帕布昔利布中间体的制备方法 |
US20200405809A1 (en) | 2018-02-27 | 2020-12-31 | Pfizer Inc. | Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor |
CN108299422B (zh) * | 2018-02-28 | 2019-10-25 | 杭州福斯特药业有限公司 | 一种帕泊昔利布中间体的制备方法 |
PL3793609T3 (pl) | 2018-05-14 | 2024-05-13 | Pfizer Inc. | Preparat w postaci doustnego roztworu |
JP6952747B2 (ja) | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ |
US20220125777A1 (en) | 2019-02-01 | 2022-04-28 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
CN109721547A (zh) * | 2019-02-11 | 2019-05-07 | 陈欣 | 一种治疗乳腺癌药物帕博西尼的中间体的制备方法 |
US20230053328A9 (en) | 2019-05-24 | 2023-02-16 | Pfizer Inc. | Combination therapies using cdk inhibitors |
US20220241412A1 (en) | 2019-05-24 | 2022-08-04 | Pfizer Inc. | Combination therapies using cdk inhibitors |
CN110143948B (zh) * | 2019-06-21 | 2021-05-14 | 上海博悦生物科技有限公司 | Cdk4/6抑制剂、其药物组合物、制备方法及应用 |
CN112920182B (zh) * | 2019-12-05 | 2023-08-01 | 上海天慈国际药业有限公司 | 一种帕布昔利布的制备方法 |
US20230117684A1 (en) | 2020-03-05 | 2023-04-20 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
TW202216131A (zh) | 2020-07-15 | 2022-05-01 | 美商輝瑞大藥廠 | 用於癌症治療之kat6抑制劑方法及組合 |
EP4181919A1 (en) | 2020-07-20 | 2023-05-24 | Pfizer Inc. | Combination therapy |
WO2022091001A1 (en) | 2020-10-29 | 2022-05-05 | Pfizer Ireland Pharmaceuticals | Process for preparation of palbociclib |
CN112457311B (zh) * | 2020-12-04 | 2022-07-12 | 江苏豪森药业集团有限公司 | 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法 |
WO2022123419A1 (en) | 2020-12-08 | 2022-06-16 | Pfizer Inc. | Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib |
CN112552297A (zh) * | 2020-12-12 | 2021-03-26 | 江西国药有限责任公司 | 一种哌柏西利的制备方法与流程 |
CN112661753B (zh) * | 2020-12-29 | 2022-06-03 | 山东铂源药业股份有限公司 | 一种帕布昔利布中间体的制备方法 |
CN112898299B (zh) * | 2021-01-26 | 2021-11-26 | 山东铂源药业有限公司 | 一种帕布昔利布中间体的制备方法 |
CN113683612B (zh) * | 2021-09-07 | 2022-06-17 | 山东铂源药业股份有限公司 | 一种帕布昔利布的制备方法 |
WO2023107525A1 (en) | 2021-12-10 | 2023-06-15 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
WO2023114264A1 (en) | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
JP2024067010A (ja) | 2022-11-02 | 2024-05-16 | ペトラ・ファーマ・コーポレイション | 疾患の治療用のホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ534069A (en) * | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
NZ544609A (en) * | 2003-07-11 | 2008-07-31 | Warner Lambert Co | Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one |
-
2007
- 2007-08-27 EP EP07804871A patent/EP2069344A2/en not_active Withdrawn
- 2007-08-27 RU RU2009108006/04A patent/RU2009108006A/ru not_active Application Discontinuation
- 2007-08-27 WO PCT/IB2007/002524 patent/WO2008032157A2/en active Application Filing
- 2007-08-27 MX MX2009002069A patent/MX2009002069A/es not_active Application Discontinuation
- 2007-08-27 CN CNA2007800334161A patent/CN101511829A/zh active Pending
- 2007-08-27 KR KR1020097007146A patent/KR20090052385A/ko not_active Application Discontinuation
- 2007-08-27 CA CA002662768A patent/CA2662768A1/en not_active Abandoned
- 2007-08-27 AU AU2007297286A patent/AU2007297286A1/en not_active Abandoned
- 2007-08-27 BR BRPI0716880-2A2A patent/BRPI0716880A2/pt not_active IP Right Cessation
- 2007-09-06 AR ARP070103937A patent/AR062680A1/es not_active Application Discontinuation
- 2007-09-07 TW TW096133457A patent/TW200821309A/zh unknown
- 2007-09-07 JP JP2007232730A patent/JP2008094834A/ja not_active Withdrawn
- 2007-09-10 US US11/852,873 patent/US7781583B2/en not_active Expired - Fee Related
-
2009
- 2009-02-23 ZA ZA200901270A patent/ZA200901270B/xx unknown
- 2009-02-25 IL IL197242A patent/IL197242A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2662768A1 (en) | 2008-03-20 |
BRPI0716880A2 (pt) | 2013-10-15 |
RU2009108006A (ru) | 2010-10-20 |
US7781583B2 (en) | 2010-08-24 |
WO2008032157A2 (en) | 2008-03-20 |
JP2008094834A (ja) | 2008-04-24 |
ZA200901270B (en) | 2010-05-26 |
KR20090052385A (ko) | 2009-05-25 |
AU2007297286A1 (en) | 2008-03-20 |
EP2069344A2 (en) | 2009-06-17 |
MX2009002069A (es) | 2009-03-06 |
CN101511829A (zh) | 2009-08-19 |
WO2008032157A3 (en) | 2008-10-23 |
TW200821309A (en) | 2008-05-16 |
US20080125588A1 (en) | 2008-05-29 |
IL197242A0 (en) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
AR091023A1 (es) | Inhibidores del nampt | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR059314A1 (es) | Derivados de las benzamidas y heteroarenos | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
AR107293A1 (es) | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g | |
AR084337A1 (es) | Azaindoles como agentes antivirales del virus respiratorio sincicial | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
AR072224A1 (es) | Derivados de pirimidona sustituidos | |
RU2013147998A (ru) | Способ получения дронедарона посредством n-бутилирования | |
ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |